Plasma partner spotlight: Coalition for Hemophilia B

03/23/2021

The Coalition for Hemophilia B’s mission is to make the quality of life the focal point of treatment for people with hemophilia B and their families through education, empowerment, advocacy, and outreach. For 30 years we have driven our mission through a family-oriented approach because hemophilia affects the whole family.

Hemophilia is a disorder in which the blood does not clot properly. The two most common types, hemophilia A and hemophilia B, are caused by defective or missing proteins that are part of the clotting system, also called the coagulation cascade. In hemophilia B, the defective or missing protein is called factor IX.

Hemophilia was originally thought to be a disorder that affects primarily males, but a significant number of females are now properly being diagnosed as having hemophilia. There are several other bleeding disorders, most caused by defects in or the absence of other proteins of the clotting system. The most common of these is von Willebrand disease. Most of the others are extremely rare.

There is no cure for hemophilia B or other bleeding disorders. They are treated primarily with replacement therapies, usually clotting factor, although many new therapies are in the late stages of development. The original clotting factor products were made primarily from human plasma, although today most patients use products made through recombinant technology. However, some patients still use plasma-derived therapies.

You can find the Coalition for Hemophilia B's blog here: www.facebook.com/HemophiliaB.

Join the Plasma Hero online community

Subscribe to Plasma Hero to get important news and updates that include hero stories and ways to get involved!

Sign up

News & Updates

Get the latest information on plasma through our news and updates. Featuring: Scientific discoveries, plasma supply, industry-related coverage, policy and legislation, and more!

Increase plasma supply by harmonizing state regulations

06/11/2024

States with regulations exceeding FDA standards create barriers for plasma centers, donors, and patients.
Read More

Plasma is a vital weapon against tetanus and rabies

05/20/2024

While tetanus and rabies are fairly rare in the United States today, these deadly diseases still pose a major global health threat. However, plasma-derived antibody products play a crucial role in treating these illnesses around the world.
Read More

Congressional Plasma Caucus formed to address concerns of constituents

04/25/2024

Members of the congressional Plasma Caucus provide a venue to educate legislators on important legislation to provide access to patients who rely on immunoglobulin (Ig) therapy.
Read More

Plasma demand is on the rise because of new patients and products

03/26/2024

The need for plasma is forecasted to increase since more patients are being diagnosed with current and newly discovered rare conditions as well as additional indications being approved for plasma medications.
Read More

Busting common plasma donation myths

02/21/2024

Misconceptions about plasma donation, such as that it is bad for your health, lead to undue misapprehensions.
Read More

How donated plasma treats trauma and shock

01/12/2024

Studies show that giving patients plasma immediately after a traumatic injury improves survival rates significantly.
Read More